Prescriptive Use To Mitigate Radiotherapy Damage To Normal Tissue and Allow More Effective Cancer Therapy. Almost 70% of all patients with cancer receive radiotherapy alone or in combination with surgery or chemotherapy. The amount of radiation that can be used to control tumor growth, however, is limited by normal tissue damage. Development of drugs to selectively reduce radiotherapy-induced normal tissue damage may improve post-therapy quality of life and allow more aggressive radiotherapy protocols to...
Preclinical studies demonstrate that TP508 injection 24 hours after lethal doses of nuclear radiation significantly increases survival. Extensive research indicates that TP508 treatment following a nuclear incident could prevent mortality in individuals exposed to high levels of radiation and reduce delayed effects of radiation to increase quality of life for survivors.
There remains a critical need for a therapeutic to be used in combination with antivirals to prevent COVID-19 progression and reduce post-recovery complications. SARS-CoV-2-induces a “cytokine storm” in the lungs and causes vascular damage throughout the body. Viral infection and cytokine-induced vascular damage initiate intravascular coagulation that leads to multiple organ failure and post-recovery damage to the brain and heart. Thus, COVID-19 is now recognized as an endothelial dysfunction-related...